Application of Sendai virus

Language

Applications of Sendai virus vectors

We provide different F-defective Sendai virus vector products and customized packaging services for global scientific research institutions and biopharmaceutical enterprises.
We are looking for agency partners worldwide. If you are interested, please contact us by email. We can now provide test products for global customers. If you have any needs, please contact us.

F-defective Sendai virus vectors

Sendai virus has various natural advantages, including non-integrability, extremely high production titer, extremely high transgenic expression performance, significant target cell breadth, and no potential pathogenicity to humans.
We are committed to promoting our unique research and development of Fgene-defective Sendai virus vector technology to the world, including virus transformation into different types of products, and providing customized carrier packaging services for scientific research institutions and biopharmaceutical enterprises.

Melton successfully completed the customization of F-defective Sendai virus samples for the CTSCB of the University of Hong Kong.

September 29,2024

Melton provides customized packaging F-defective Sendai virus service for CTSCB of the University of Hong Kong.

MeltonVEC™-Cell Fusion Kit (HVJ): Supplementary description

October 03,2024

Our company produces the "MeltonVEC-Cell Fusion Kit", which operates on the same principle as the "GenomONE-CF EX" product. The cell fusion efficiency exceeds 75%, and the usage method is nearly identical. PBS may be used to resuspend the freeze-dried product.

Application of Sendai virus-“Sendai virus-mediated RNA delivery restores fertility to congenital and chemotherapy-induced infertile female mice”

October 07,2024

The article discusses the research on the use of Sendai virus (SeV) for treating congenital and chemotherapy-induced infertility. The study shows that SeV successfully restores fertility in mice by enhancing KITL expression without the risk of viral gene integration. SeV therapy demonstrates potential for protecting fertility and offers new insights for future clinical applications.

Product Evaluation - Testing iPSC Reprogramming of Fibroblasts Using MeltonVEC™-Sendai iPSC Reprogramming Kit (Including Experimental Methods)

October 17,2024

This article describes how one of our customers who applied MeltonVEC-Sendai iPSC Reprogramming Kit on the transduction of newborn fibroblasts into iPSCs successfully. There are detailed materials and methodology, highly illustrated results in this informative article.

MeltonVEC™-Cell Fusion Kit (HVJ-E) (Freeze Dried) has started global deliveries.

October 27,2024

The MeltonVEC™-Cell Fusion Kit (HVJ-E) (Freeze Dried) has started global deliveries and has been successfully shipped to the UAE, currently completing order deliveries to other countries.

Dose‑escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ‑E) against chemotherapy‑resistant malignant pleural mesothelioma: a clinical tria

November 02,2024

This phase I study evaluated HVJ-E, an inactivated Sendai virus particle, for safety and preliminary efficacy in chemotherapy-resistant MPM. High doses led to stable disease, while low doses saw progression, indicating a dose-dependent antitumor effect with no serious adverse events. Findings support a phase II trial with higher doses. Trial registration: UMIN000019345.

MeltonVEC™-Cell Fusion Kit (HVJ-E) (Freeze dried) product has been successfully delivered to the U.S. customer.

November 09,2024

MeltonVEC™-Cell Fusion Kit (HVJ-E) (Freeze dried) product has now been delivered to the US customers following the UAE delivery.

Hemagglutinating Virus of Japan Envelope (HVJ-E)-Guided Gene Transfer to the Intestinal Epithelium

November 10,2024

The passage introduces intestine-specific gene transfer (iGT), a method for delivering small molecules like siRNAs and plasmids into the intestinal epithelium of living mice using the Hemagglutinating Virus of Japan Envelope (HVJ-E). This technique offers a faster and more efficient alternative to traditional genetic engineering in mice, aiding research on intestinal stem cell-driven tissue renewal and tumorigenesis.

Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)

November 09,2024

"Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)" is a preliminary study showing that oncolytic Sendai virus (SeV) can inhibit tumor growth in canine mast cell tumors (MCT) by selectively targeting and destroying tumor cells. This research provides early evidence for SeV as a potential cancer therapy and supports future clinical trials.

Generation of mitochondrial replacement monkeys by female pronucleus transfer-Chinese Academy of Sciences

November 18,2024

This study created four healthy cynomolgus monkeys using pronuclear transfer, with minimal mtDNA carryover and stable mtDNA dynamics. It highlights the potential of this method for preventing mtDNA diseases and advancing mitochondrial replacement therapies in humans.T（The subsequent HVJ-E cell fusion reagent product procurement from the Chinese Academy of Sciences(Shanghai) has been replaced with Melton's.)

“All in one” lipid-polymer nanodelivery system for gene therapy of ischemic diseases

November 27,2024

This study develops lipid-polymer hybrid nanocarriers (FLNPs) to enhance gene delivery for ischemic diseases. FLNPs improve gene transfection, avoid lysosomes, and target the nucleus. Loaded with Hepatocyte Growth Factor (pHGF) and Catalase (pCAT) plasmids, FLNPs boosted cell resistance to oxidative stress and improved recovery in a mouse ischemia model, without causing metabolic disturbances. FLNPs show promise for effective gene therapy in ischemia.

About Us

Melton (Shenzhen) Biomedical Technology Company Limited makes use of the latest cutting-edge technologies in the field of life sciences to develop its core technology of the F-defective recombinant Sendai virus vectors, which have the advantages of ultra-high transfection efficiency and safety without integrating its genetic material into human chromosomes.

Melton's Mission
Our mission is committed to promoting recombinant Sendai virus vector technology to the world and contributing to the global healthcare sector.

Contact Us

Technical inquiries and product quotation

FirstName*

LastName

Email*

Message*

Describe the question you would like to inquire about

About us: consectetur adipisc ing elit, sed do Eiusmod Tempor inci didunt ut labore et dolore

View More

Contact Us: Shenzhen City ,Guangdong Province, China +86; [email protected]; +86 755-84899046

Newsletter: Lorem ipsum dolor si consectetur adipisicing elit, sed eiusmotempor incididunt ut labore et

Follow Us